SCHEMBL18602020

SCHEMBL18602020

CCC(C)C(C(CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(Cc1ccccc1)C(=O)O)OC)N(C)C(=O)CNC(=O)C(C(C)C)N(C)C

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.37
SSTR2 P30874 2/20 0.37
ACE P12821 8/20 0.37
CTSD P07339 2/20 0.36
CTSE P14091 2/20 0.36
BACE1 P56817 1/20 0.36
ACE2 Q9BYF1 5/20 0.35
MME P08473 4/20 0.35
CPA1 P15085 4/20 0.35
LNPEP Q9UIQ6 2/20 0.35
ANPEP P15144 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HSD17B10 Q99714 1/20 0.35
RAMP1 O60894 1/20 0.34
CALCRL Q16602 1/20 0.34
OPRD1 P41143 1/20 0.34
FOLH1 Q04609 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15811693 1.00 CYP3A4 (0.37) CYP3A4SSTR2ACECTSDCTSE
SCHEMBL22419930 1.00 CYP3A4 (0.37) CYP3A4SSTR2ACECTSDCTSE
SCHEMBL19841574 1.00 CYP3A4 (0.37) CYP3A4SSTR2ACECTSDCTSE
SCHEMBL20750952 0.95 SSTR2 (0.38) CYP3A4SSTR2CTSDCTSEBACE1
SCHEMBL24837336 0.94 SSTR2 (0.38) CYP3A4SSTR2ACECTSDCTSE
SCHEMBL23894126 0.94 SSTR2 (0.37) CYP3A4SSTR2ACECTSDCTSE
SCHEMBL24201085 0.94 SSTR2 (0.38) CYP3A4SSTR2ACECTSDCTSE
SCHEMBL23626306 0.94 CTSD (0.37) CYP3A4SSTR2ACECTSDCTSE
SCHEMBL21782040 0.94 CTSD (0.37) CYP3A4SSTR2ACECTSDCTSE
SCHEMBL20749835 0.94 CTSD (0.37) CYP3A4SSTR2ACECTSDCTSE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357259-A1 BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-11-09 US disclosed
WO-2021050917-A1 PHOSPHOLIPID ETHER CONJUGATES AS CANCER-TARGETING DRUG VEHICLES CELLECTAR BIOSCIENCES, INC. (US) 2021-03-18 WO disclosed
EP-2928504-B1 PROTEIN-POLYMER-DRUG CONJUGATES MERSANA THERAPEUTICS INC (US) 2019-02-20 EP disclosed
EP-2717916-B1 PROTEIN-POLYMER-DRUG CONJUGATES MERSANA THERAPEUTICS INC (US) 2017-03-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357259-A1 BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF DOCK11, PAICS, RHOA CYP3A4 3557/4885SSTR2 2548/4885ACE 4359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.